After Teva launched its generic Sensipar for a matter of days, Amgen and Teva now have a patent deal delaying the generic drugmaker's rollout until mid-2021.
Amgen’s Sensipar is yet another example of the complicated process of anticipating generic launches. The drug's primary patent expired March 8, but it also boasts a 2026 formulation patent that it’s using to try to defend its blockbuster.
